Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
130 hedge funds and large institutions have $236M invested in Catalyst Pharmaceutical in 2019 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 47 increasing their positions, 34 reducing their positions, and 17 closing their positions.
76% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 17
38% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 34
11% more funds holding
Funds holding: 117 → 130 (+13)
1.15% more ownership
Funds ownership: 59.82% → 60.98% (+1.2%)
28% less capital invested
Capital invested by funds: $327M → $236M (-$91.5M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
79% less call options, than puts
Call options by funds: $70K | Put options by funds: $340K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$23.8M |
| 2 |
State Street
Boston,
Massachusetts
|
+$17.7M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$8.18M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$7.33M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$5.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$94.9M |
| 2 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$6.24M |
| 3 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$5.75M |
| 4 |
AI
Atom Investors
Austin,
Texas
|
-$5.38M |
| 5 |
BC
Broadfin Capital
New York
|
-$4.67M |
CPRX Hedge Fund Activity: Q4 2019 in Review
130 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q4 2019, worth a combined $236M — down 28% from $327M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new CPRX positions and 17 closed out — a net gain of 13 holders — while 47 added to existing stakes and 34 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $23.8M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $94.9M sold.
- 130 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q4 2019, up from 117 in Q3 2019.
- Funds reported $236M of Catalyst Pharmaceutical stock for Q4 2019, down 28% quarter-over-quarter.
- 30 funds opened new Catalyst Pharmaceutical positions in Q4 2019 and 17 closed out, a net change of +13 holders.
- The largest Catalyst Pharmaceutical buyer in Q4 2019 was Armistice Capital, an estimated $23.8M added.
- The largest Catalyst Pharmaceutical seller in Q4 2019 was Consonance Capital Management, an estimated $94.9M sold.
Based on aggregated 13F filings for Q4 2019.